Abstract
First-generation drug-eluting stents (DES) have been associated with impaired localized coronary vasomotion and delayed endothelialization. We aimed to compare coronary vasomotion after implantation of a newer-generation everolimus-eluting stent (EES), with a first-generation paclitaxel-eluting stent (PES). Coronary vasomotion was studied in 19 patients with EES and 13 with PES. Vasomotor response was measured proximally and distally to the stent and in a remote vessel (reference segment). Quantitative coronary angiography was performed offline. Endothelium independent vasomotion did not differ significantly between the two groups. EES showed significant vasodilatation while PES showed vasoconstriction at both proximal (+4.5 ± 3.6 vs −4.2 ± 6.9, p < 0.001) and distal (+4.6 ± 7.9 vs −4.8 ± 9.3, p = 0.003) segments. The reference segment did not show any significant difference in vasodilatation between the two groups (+9.8 ± 6.4 vs +7.2 ± 5.2, p = 0.17). Endothelium-dependent vasomotion at adjacent stent segments is relatively preserved after EES implantation while vasoconstriction was observed after PES implantation.
Similar content being viewed by others
References
Stettler, C., Wandel, S., Allemann, S., et al. (2007). Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 370, 937–948.
Camenzind, E., Steg, P. G., & Wijns, W. (2007). Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation, 115, 1440–1455. discussion 1455.
Windecker, S., & Jüni, P. (2008). Safety of drug-eluting stents. Nature Clinical Practice. Cardiovascular Medicine, 5, 316–328.
Finn, A. V., Nakazawa, G., Joner, M., et al. (2007). Vascular responses to drug eluting stents: importance of delayed healing. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1500–1510.
Van Beusekom, H. M., Saia, F., Zindler, J. D., et al. (2007). Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. European Heart Journal, 28, 974–979.
Joner, M., Finn, A., Farb, A., et al. (2006). Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. Journal of the American College of Cardiology, 48, 193–202.
Finn, A. V., Joner, M., Nakazawa, G., et al. (2007). Pathological correlates of late drug-eluting stent thrombosis. Strut coverage as a marker of endothelialization. Circulation, 115, 2435–2441.
Togni, M., Windecker, S., Cocchia, R., et al. (2005). Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. Journal of the American College of Cardiology, 46, 231–236.
Hofma, S., Van der Giessen, W., Van Dalen, B., et al. (2006). Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. European Heart Journal, 27, 166–170.
Togni, M., Räber, L., Cocchia, R., et al. (2007). Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. International Journal of Cardiology, 120, 212–220.
Hamilos, M. I., Ostojic, M., Beleslin, B., NOBORI CORE investigators, et al. (2008). Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. Journal of the American College of Cardiology, 51, 2123–2129.
Hamilos, M., Sarma, J., Ostojic, M., et al. (2008). Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circulation. Cardiovascular Interventions, 1, 193–200.
Wiemer, M., Seth, A., Chandra, P., et al. (2008). Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. American Heart Journal, 156, 751–757.
Torguson, R., & Waksman, R. (2008). Overview of the 2007 food and drug administration circulatory system devices panel meeting on the Xience V everolimus-eluting coronary stent. American Journal of Cardiology, 102, 1624–1630.
Stone, G. W., Midei, M., Newman, W., SPIRIT III Investigators, et al. (2009). Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation, 119, 680–686.
Stone, G. W., Rizvi, A., Newman, W., SPIRIT IV Investigators, et al. (2010). Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New England Journal of Medicine, 362, 1663–1674.
Onuma, Y., Kukreja, N., Piazza, N., Interventional Cardiologists of the Thoraxcenter (2000 to 2007), et al. (2009). The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. Journal of the American College of Cardiology, 54, 269–276.
Kedhi, E., Joesoef, K. S., McFadden, E., et al. (2010). Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet, 375, 201–209.
Axel, D. I., Kunert, W., Goggelmann, C., et al. (1997). Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 96, 636–645.
John, M. C., Wessely, R., Kastrati, A., et al. (2008). Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC. Cardiovascular Interventions, 1, 535–544.
Joner, M., Nakazawa, G., Finn, A. V., et al. (2008). Endothelial cell recovery between comparator polymer-based drug-eluting stents. Journal of the American College of Cardiology, 52, 333–342.
Serruys, P. W., Onuma, Y., Ormiston, J. A., et al. (2010). Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation, 122, 2301–2312.
Simon, C., Palmaz, J. C., & Sprague, E. A. (2000). Influence of topography on endothelialization of stents: clues for new designs. Journal of Long-Term Effects of Medical Implants, 10, 143–151.
Acknowledgments
We would like to thank all interventional cardiologists and staff at the participating sites for contributing in one way or the other to this study. Dr. Dragica Paunovic has been instrumental in initiating and supporting the joint research programs between Aalst and Belgrade.
Funding Sources
This work was supported in part by the Meijer Lavino Foundation for Cardiac Research.
Author information
Authors and Affiliations
Corresponding author
Additional information
Associate Editor Angela Taylor oversaw the review of this article
Rights and permissions
About this article
Cite this article
Hamilos, M., Ribichini, F., Ostojic, M.C. et al. Coronary Vasomotion One Year after Drug-Eluting Stent Implantation: Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents. J. of Cardiovasc. Trans. Res. 7, 406–412 (2014). https://doi.org/10.1007/s12265-014-9568-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-014-9568-2